Global Benign Prostatic Hyperplasia Treatment Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Benign Prostatic Hyperplasia Treatment Market By 2030 Starting From Its 2026 Size?
The benign prostatic hyperplasia treatment market size has experienced robust growth in recent years. It is projected to expand from $8.69 billion in 2025 to $9.17 billion in 2026, showing a compound annual growth rate (CAGR) of 5.6%. The market’s past growth can be attributed to an increasing aging male population, a rising prevalence of urinary disorders, the expansion of urology specialty services, a growing adoption of pharmacological treatments, and enhanced access to diagnostic screening.
The benign prostatic hyperplasia treatment market size is anticipated to undergo significant expansion in the coming years. It is projected to climb to $11.29 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.3%. This expected increase during the forecast period can be ascribed to a growing embrace of robotic-assisted prostate procedures, an elevated focus on personalized treatment planning, the broadening of home-based therapy alternatives, the expanding integration of digital patient monitoring instruments, and an escalating demand for minimally invasive interventions. Prominent trends for the forecast period include the increasing adoption of minimally invasive surgical approaches, a rising need for targeted drug therapies, the expanding utilization of combination treatment methods, the proliferation of outpatient treatment environments, and an intensified concentration on symptom management and improving quality of life.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp
What Drivers Are Shaping The Future Growth Of The Benign Prostatic Hyperplasia Treatment Market?
The benign prostatic hyperplasia treatment market is expected to grow due to the increasing adoption of minimally invasive surgeries. These surgical procedures involve small or no incisions, employing specialized instruments to reduce recovery time, pain, and the risk of complications. The rising preference for minimally invasive surgeries is fueled by advantages such as quicker recovery times, less pain, lower risk of complications, and improved cosmetic outcomes. When applied to benign prostatic hyperplasia treatment, minimally invasive surgeries offer patients reduced recovery times, decreased risks of complications, and effective symptom relief, thereby enhancing overall surgical outcomes. For instance, in September 2023, according to the American Society of Plastic Surgeons (ASPS), a U.S.-based professional association, approximately 25.4 million minimally invasive cosmetic procedures were performed in 2023, representing a 7% increase from 23.7 million in 2022. Consequently, the growing utilization of minimally invasive surgeries is driving the expansion of the benign prostatic hyperplasia treatment market.
Which Segment Categories Define The Benign Prostatic Hyperplasia Treatment Market?
The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy
Which Market Trends Are Creating New Opportunities In The Benign Prostatic Hyperplasia Treatment Market?
Major companies operating in the benign prostatic hyperplasia treatment market are prioritizing the development of innovative solutions, such as intraprostatic drug elution therapy, to secure a competitive advantage. This therapy involves the direct placement of a bioabsorbable implant into the prostate, facilitating the localized, sustained delivery of a therapeutic agent. For instance, in May 2025, Resurge Therapeutics, a US-based urology technology developer, introduced a paclitaxel-eluting bioabsorbable implant for BPH, offering office-based deployment, targeted drug release, and minimal post-procedure pain. This localized delivery method reduces systemic exposure, boosts efficacy, and helps preserve sexual function. However, its long-term safety and large-scale adoption are still under evaluation.
Who Are The Top Companies Competing In The Benign Prostatic Hyperplasia Treatment Market?
Major companies operating in the benign prostatic hyperplasia treatment market are Astellas Pharma Inc., Bayer AG, Pfizer Inc., Merck & Co Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi S.A., Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, Cook Medical Incorporated, Coloplast Group, Medtronic Public Limited Company, Urovant Sciences Ltd., UroGen Pharma Ltd., Urologix Inc., Zenflow Inc., HistoSonics Inc.
Read the full benign prostatic hyperplasia treatment market report here:
Which Geographic Regions Are Influencing Demand In The Benign Prostatic Hyperplasia Treatment Market?
North America was the largest region in the benign prostatic hyperplasia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Benign Prostatic Hyperplasia Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21112&type=smp
Browse Through More Reports Similar to the Global Benign Prostatic Hyperplasia Treatment Market 2026, By The Business Research Company
Drugs For Benign Prostatic Hypertrophy Global Market Report
Prostate Cancer Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
